Arcutis’ Zoryve (roflumilast) Receives the US FDA's NDA Approval for Plaque Psoriasis in Individuals Aged ≥12 Years
- The US FDA has approved the NDA for Zoryve (0.3%) for PsO, incl. intertriginous areas in patients aged ≥12yrs. The therapy is expected to be available in mid-August
- The therapy has been shown to rapidly clear plaques & reduce itch across all areas of the body & was found to be safe & well tolerated in multiple clinical trials with improvements in disease clearance in hard-to-treat areas
- The company has launched a ZORYVE patient support program that provides access to commercially insured patients to use Zoryve & offers the payer process, lowering the out-of-pocket cost for eligible patients. The company offers Arcutis Cares PAP which will give Zoryve to financially qualified patients who are uninsured or underinsured at free cost
Ref: Arcutis | Image: Arcutis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.